Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:

17 Dec 2010

Study finds occurrence of infection following surgical procedures

Delaying elective surgical procedures after a patient has been admitted to the hospital significantly increases the risk of infectious complications and raises hospital costs, according to the results of a new study in the December issue of the Journal of the American College of Surgeons.

16 Dec 2010

FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension for use in stress echocardiography.

14 Dec 2010

U-M's participation in Medicare Physician Group Practice Demonstration Project helps save over $15 million

Medicare patients with a host of physical problems are getting better care at the University of Michigan Health System, and U-M staff have saved more than $15 million on the cost of that care over four years.

13 Dec 2010

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.

9 Dec 2010

Study examines impact of poor care coordination on quality, cost of care in America

Many Americans seek medical treatment from a variety of care providers and often must play the role of informing each doctor what the others are recommending or prescribing. This fragmented experience of poorly coordinated care is due in part to a lack of consistent systems and processes in place to coordinate care across providers and facilities.

8 Dec 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Cephalon, Inc. and Mesoblast Limited, today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

8 Dec 2010

Physician-led models of care benefit patients, health system

To best meet the goals of optimized, coordinated patient care and also help curb health care costs, physicians should be the heart of accountable care organizations (ACOs), an evolving model of patient care. The American Medical Association today outlined recommendations to make this a reality in comments provided to the Center for Medicare and Medicaid Services (CMS).

2 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of golimumab 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

30 Nov 2010

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). The multi-center, randomized, placebo-controlled, double-blind trial is known as the REVERSE Trial.

30 Nov 2010

Largest remote health monitoring project in the world launched in China

Canada-based IDEAL LIFE and China's Shandong NovaTech Biological Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer and medical products distribution network in China, announced the launch of the largest remote health monitoring project in the world, bringing wireless, remote health monitoring to the People's Republic of China.

30 Nov 2010

Tricare may raise fees; VA Medical Center uses telemedicine to trim costs

"Of nearly 4.5 million military retirees and their families, about three-quarters are estimated to have access to health insurance through a civilian employer or group. But more than two million of them stay on Tricare," the military's lifetime health insurance program, The New York Times reports. Enrollment in Tricare, which costs less than what many private employers ask for in premiums, is expected to grow "as the costs of private health care continue to climb."

29 Nov 2010

U.S mortality rate from congenital heart defects drops 24%: Report

The U.S. death rate from congenital heart defects dropped 24 percent from 1999 to 2006 among children and adults, according to research reported in Circulation: Journal of the American Heart Association.

23 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

FDA approves new drug application for NEXTERONE Premixed Injection

Prism Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration has approved the supplemental new drug application for NEXTERONE (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent amiodarone IV.

19 Nov 2010

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses.

18 Nov 2010

LVNC cardiomyopathy associated with heart failure, stroke and ventricular arrhythmias

Left ventricular non-compaction (LVNC), a cardiomyopathy about which little is fully understood, is associated with heart failure (HF), stroke and ventricular arrhythmias, according to a study to be presented Nov. 17 at the 2010 American Heart Association (AHA) Scientific Sessions in Chicago. The researchers also will report that advanced imaging technologies reveal that developing these cardiac risks appear to progress over time in patients with LVNC.

18 Nov 2010

NT-proBNP guided heart failure care associated with reduced cardiovascular events

Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death

From Roche Sequencing and Life Science 17 Nov 2010

Congestive Heart Failure News and Research

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Study finds occurrence of infection following surgical procedures

FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography

U-M's participation in Medicare Physician Group Practice Demonstration Project helps save over $15 million

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Study examines impact of poor care coordination on quality, cost of care in America

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Physician-led models of care benefit patients, health system

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Golimumab with methotrexate improves markers of inflammation and structural damage in RA patients

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Largest remote health monitoring project in the world launched in China

Tricare may raise fees; VA Medical Center uses telemedicine to trim costs

U.S mortality rate from congenital heart defects drops 24%: Report

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

FDA approves new drug application for NEXTERONE Premixed Injection

CDC data: Adults remain unvaccinated against preventable infectious illnesses

LVNC cardiomyopathy associated with heart failure, stroke and ventricular arrhythmias

NT-proBNP guided heart failure care associated with reduced cardiovascular events

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News